Pricing
  1. US-listed companies
  2. Arcadia Biosciences, Inc.
  3. Financials
  4. Cash from operations

Arcadia Biosciences, Inc. (RKDA)

Market cap
$2.52M
P/E ratio
SummaryFinancials
Period EndCash from operations (Million USD)YoY (%)
Dec 31, 2024-10-37.25%
Dec 31, 2023-15+9.29%
Dec 31, 2022-14-45.95%
Dec 31, 2021-26-14.29%
Dec 31, 2020-30+75.71%
Dec 31, 2019-17+26.17%
Dec 31, 2018-14-2.39%
Dec 31, 2017-14-18.12%
Dec 31, 2016-17+12.88%
Dec 31, 2015-15

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat